A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

NCT07589244 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

DRUG: VRT106
DRUG: VRT106 in combination with camrelizumab and apatinib
DRUG: Investigator's Choice of Standard of Care

Sponsor

Guangzhou Virotech Pharmaceutical Co., Ltd.